Join the Apretude group to help and get support from people like you.
Apretude News
Long-Lasting HIV Prevention Shot Headed Toward Approval
FRIDAY, June 6, 2025 — A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month. If approved, the shot — lenacapavir — would be given t...
Trump Administration Waives Halt on Distribution of HIV Medications Via PEPFAR
WEDNESDAY, Jan. 29, 2025 – The Trump administration has made some concessions to the halt placed on distributions of global HIV treatments via the U.S. President's Emergency Plan for AIDS Relief...
Preexposure Prophylaxis Use for HIV Increased in Recent Years
MONDAY, Oct. 21, 2024 – Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oct. 14 in the Journal of the American Medical ...
Long-Acting Cabotegravir Well Tolerated in Pregnant Women
THURSDAY, Aug. 8, 2024 – Long-acting injectable cabotegravir (CAB-LA) appears to be well tolerated in pregnant women, according to a study presented at AIDS 2024, the 25th International AIDS...
Long-Acting Early Viral Inhibition Described in Context of Long-Acting Injectable Cabotegravir
MONDAY, July 29, 2024 – In a research letter published online July 24 in the New England Journal of Medicine, the authors describe long-acting early viral inhibition (LEVI) among patients with acute...
FDA Approves Apretude (cabotegravir extended-release injectable suspension) for HIV Pre-Exposure Prophylaxis (PrEP)
LONDON--(BUSINESS WIRE) December 20, 2021 --ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi)...